LUNG CANCER

At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Natasha Leighl, MD, MMSc, BSc, discussed the analysis of the CHRYSALIS study that was presented at the 2024 American Association for Cancer Research Annual Meeting.

There is currently 1 FDA-approved antibody-drug conjugate available for patients with non-small cell lung cancer, and several more potentially coming down the pike.

An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.

During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.

Findings from recent clinical research have firmly entrenched the use of neoadjuvant immune checkpoint blockade in the treatment of early-stage non-small cell lung cancer.

In an interview with Targeted Oncology, Jonathan Spicer, MD, discussed the background and findings of the KEYNOTE-671 trial of perioperative pembrolizumab in non-small cell lung cancer.

Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.

The combination of pembrolizumab and olaparib did not appear to improve overall or progression-free survival in patients with nonsquamous non-small cell lung cancer.

Carlos Rojas, MD, discusses the next steps for evaluating MK-1084 in a phase 1 trial for the first-line treatment of metastatic non-small cell lung cancer and advanced solid tumors.

Data from the phase 3 POSEIDON trial support the use of tremelimumab, durvalumab, and chemotherapy for patients with metastatic non–small cell lung cancer, including harder-to-treat subgroups, in the first-line.

In the first article of a 2-part series, Christine Bestvina, MD, discussed the role of the newer tyrosine kinase inhibitor repotrectinib for patients with non–small cell lung cancer that is positive for a ROS1 mutation.

The FDA has accepted the new drug application of ensartinib for the treatment of patients with metastatic ALK-positive non-small cell lung cancer.

Carlos Rojas, MD, discusses the mechanism of action of MK-1084, a selective KRAS G12C inhibitor.

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.

Third-line combination of THIO and cemiplimab improved overall response rate compared with standard of care in patients with non-small cell lung cancer.

Discuss emerging data and therapies to optimize future treatment.

Following the development of further safety and monitoring protocols, the IOV-LUN-202 trial can resume patient enrollment.

Overview of side effects and management when combining these agents.

Highlight key findings in the KRYSTAL-7 trial.

The FDA has granted a breakthrough therapy designation to BAY 2927088 for the treatment of non-small cell lung cancer harboring HER2-activating mutations.

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Hatim Husain, MD, explained the significance of the PACIFIC trial and its real-world counterpart PACIFIC-R looking at the use of durvalumab after chemotherapy and radiation in patients with unresectable stage III non–small cell lung cancer.

In 2 separate live virtual events, Firas B. Badin, MD, MBA, and Sandip P. Patel, MD, review a case of a patient with non–small cell lung cancer with their respective groups and discuss the best options for therapy.

Analyze the appropriate washout period when switching between KRAS inhibitors.